Weekly Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings

May 17, 2018 - By Darrel Chase

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
Big Money Sentiment increased to 1.66 in Q4 2017. It has change of 0.40, from 2017Q3’s 1.26. The ratio increased due to Halozyme Therapeutics, Inc. positioning: 13 sold and 45 reduced. 39 funds took holdings and 57 increased holdings. Investors holded 118.53 million in 2017Q3 but now own 118.31 million shares or 0.18% less.
Guggenheim Cap Ltd Limited Liability Company invested in 160,847 shs or 0.01% of the stock. Artal Gru invested in 150,000 shs or 0.05% of the stock. Clarivest Asset Mgmt, a California-based fund reported 50,186 shs. Macquarie Grp Limited stated it has 504,100 shs or 0.02% of all its holdings. 12,200 are held by Numeric Invsts. Horizon Kinetics Ltd holds 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 19,208 shs. United Kingdom-based Pictet Asset Mngmt Ltd has invested 0.13% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Baker Bros L P holds 0.28% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 1.58M shs. Nomura Asset Ltd, Japan-based fund reported 16,000 shs. Jacobs Levy Equity Mgmt stated it has 0.03% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Amer Century Inc accumulated 0.01% or 552,991 shs. Rhumbline Advisers has 126,811 shs. Susquehanna International Grp Limited Liability Partnership invested in 0% or 293,691 shs. Suntrust Banks holds 12,882 shs or 0% of its capital. D E Shaw And Commerce Inc invested in 252,736 shs.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 1, while 2 are “Hold”. (NASDAQ:HALO) has 50% bullish analysts. 9 are the (NASDAQ:HALO)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Wednesday, January 24 the rating was maintained by Deutsche Bank with “Buy”. On Wednesday, February 21 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Overweight” rating given by JP Morgan. On Wednesday, November 22 the firm has “Hold” rating given by Barclays Capital. On Thursday, February 22 the company was maintained by BMO Capital Markets. On Wednesday, February 21 Canaccord Genuity maintained the shares of HALO in report with “Buy” rating. On Monday, May 14 the firm has “Buy” rating given by Canaccord Genuity. On Friday, May 11 the firm has “Underweight” rating by Barclays Capital given. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0
22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade

HALO is reaching $18.16 during the last trading session, after decreased 2.47%.Halozyme Therapeutics, Inc. has volume of 644,666 shares. Since May 17, 2017 HALO has risen 32.10% and is uptrending. HALO outperformed by 20.55% the S&P 500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The company has $2.60 billion market cap. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 40.36. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by Seekingalpha.com, Benzinga.com and Benzinga.com. The first one has “Premarket analyst action – healthcare” as a title and was published on May 11, 2018. The next is “22 Stocks Moving In Friday’s Pre-Market Session” on May 11, 2018. And last was published on May 11, 2018, called “38 Stocks Moving In Friday’s Mid-Day Session”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.